Article Excerpt: Patient recruitment has begun in a National Institutes of Health (NIH) trial of two digital therapeutics (DTx) for people with opioid use disorder (OUD), developed by Pear Therapeutics and Chess Health. The CTN-0100 study is test strategies to help keep people with OUD on drug treatment, improve the chances that those stabilised with drug treatments for OUD can come off medication without relapsing, as well as to find ways to predict the risk of relapse based on patient characteristics. The study is testing various drug regimens along with Pear’s prescription app reSET-O and Chess Health’s free Connections app, given on top of standard medical management for OUD.
Full Article: https://tinyurl.com/efpbcj5a
Article Source: Pharmaphorum